BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34686499)

  • 1. Activation of
    Biran A; Yin S; Kretzmer H; Ten Hacken E; Parvin S; Lucas F; Uduman M; Gutierrez C; Dangle N; Billington L; Regis FF; Rassenti LZ; Mohammad A; Hoffmann GB; Stevenson K; Zheng M; Witten E; Fernandes SM; Tausch E; Sun C; Stilgenbauer S; Brown JR; Kipps TJ; Aster JC; Gnirke A; Neuberg DS; Letai A; Wang L; Carrasco RD; Meissner A; Wu CJ
    Cancer Res; 2021 Dec; 81(24):6117-6130. PubMed ID: 34686499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
    Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon regulatory factor 4 attenuates Notch signaling to suppress the development of chronic lymphocytic leukemia.
    Shukla V; Shukla A; Joshi SS; Lu R
    Oncotarget; 2016 Jul; 7(27):41081-41094. PubMed ID: 27232759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
    Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
    Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
    Boudny M; Zemanova J; Khirsariya P; Borsky M; Verner J; Cerna J; Oltova A; Seda V; Mraz M; Jaros J; Jaskova Z; Spunarova M; Brychtova Y; Soucek K; Drapela S; Kasparkova M; Mayer J; Paruch K; Trbusek M
    Haematologica; 2019 Dec; 104(12):2443-2455. PubMed ID: 30975914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells.
    Rosati E; Sabatini R; Rampino G; Tabilio A; Di Ianni M; Fettucciari K; Bartoli A; Coaccioli S; Screpanti I; Marconi P
    Blood; 2009 Jan; 113(4):856-65. PubMed ID: 18796623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma.
    Lucas F; Rogers KA; Harrington BK; Pan A; Yu L; Breitbach J; Bundschuh R; Goettl VM; Hing ZA; Kanga P; Mantel R; Sampath D; Smith LL; Wasmuth R; White DK; Yan P; Byrd JC; Lapalombella R; Woyach JA
    Clin Cancer Res; 2019 Oct; 25(20):6260-6273. PubMed ID: 31296529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle.
    Caraballo JM; Acosta JC; Cortés MA; Albajar M; Gómez-Casares MT; Batlle-López A; Cuadrado MA; Onaindia A; Bretones G; Llorca J; Piris MA; Colomer D; León J
    Oncotarget; 2014 Jul; 5(13):4694-708. PubMed ID: 25051361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas.
    Ryan RJH; Petrovic J; Rausch DM; Zhou Y; Lareau CA; Kluk MJ; Christie AL; Lee WY; Tarjan DR; Guo B; Donohue LKH; Gillespie SM; Nardi V; Hochberg EP; Blacklow SC; Weinstock DM; Faryabi RB; Bernstein BE; Aster JC; Pear WS
    Cell Rep; 2017 Oct; 21(3):784-797. PubMed ID: 29045844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SENP2 exerts an anti‑tumor effect on chronic lymphocytic leukemia cells through the inhibition of the Notch and NF‑κB signaling pathways.
    Chen XL; Wang SF; Liang XT; Liang HX; Wang TT; Wu SQ; Qiu ZJ; Zhan R; Xu ZS
    Int J Oncol; 2019 Feb; 54(2):455-466. PubMed ID: 30431078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Notch signal pathway and chronic lymphocytic leukemia].
    Zhang JY; Xu ZS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1472-5. PubMed ID: 25338610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. γ-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation.
    Rosati E; Sabatini R; De Falco F; Del Papa B; Falzetti F; Di Ianni M; Cavalli L; Fettucciari K; Bartoli A; Screpanti I; Marconi P
    Int J Cancer; 2013 Apr; 132(8):1940-53. PubMed ID: 23001755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
    Chiang CL; Goswami S; Frissora FW; Xie Z; Yan PS; Bundschuh R; Walker LA; Huang X; Mani R; Mo XM; Baskar S; Rader C; Phelps MA; Marcucci G; Byrd JC; Lee LJ; Muthusamy N
    Blood; 2019 Aug; 134(5):432-444. PubMed ID: 31151986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
    Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
    Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia.
    Tardivon D; Antoszewski M; Zangger N; Nkosi M; Sordet-Dessimoz J; Hendriks R; Koch U; Radtke F
    Blood; 2021 Jun; 137(22):3079-3092. PubMed ID: 33512383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia.
    Xiong H; Mancini M; Gobert M; Shen S; Furtado GC; Lira SA; Parkhurst CN; Garambois V; Brengues M; Tadokoro CE; Trimarchi T; Gómez-López G; Singh A; Khiabanian H; Minuzzo S; Indraccolo S; Lobry C; Aifantis I; Herranz D; Lafaille JJ; Maraver A
    Theranostics; 2021; 11(4):1594-1608. PubMed ID: 33408769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL.
    Hubmann R; Schnabl S; Araghi M; Schmidl C; Rendeiro AF; Hilgarth M; Demirtas D; Ali F; Staber PB; Valent P; Zielinski C; Jäger U; Shehata M
    Cells; 2020 Jun; 9(6):. PubMed ID: 32570839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC.
    Benatti S; Atene CG; Fiorcari S; Mesini N; Martinelli S; Zucchini P; Bacchelli F; Maccaferri M; Debbia G; Potenza L; Rossi D; Vallisa D; Trentin L; Gaidano G; Luppi M; Marasca R; Maffei R
    Hematol Oncol; 2021 Dec; 39(5):707-711. PubMed ID: 34431535
    [No Abstract]   [Full Text] [Related]  

  • 19. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
    Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
    Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells.
    Krysov S; Dias S; Paterson A; Mockridge CI; Potter KN; Smith KA; Ashton-Key M; Stevenson FK; Packham G
    Blood; 2012 Jan; 119(1):170-9. PubMed ID: 22086413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.